



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 56692

**Title:** Immune infiltration-associated SA Y predicts favorable prognosis for HCC

**Reviewer's code:** 04091933

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Senior Researcher

**Reviewer's Country/Territory:** Russia

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-05-10

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-06-10 21:25

**Reviewer performed review:** 2020-06-17 23:00

**Review time:** 7 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The research topic seems to be truly relevant given the high global incidence of HCC. The search for biomarkers is important not only for diagnosis, but also for assessing tumor progression. SAA1 is regarded as the important biomarker in inflammation and malignancy, but its biological role has not been fully understood despite extensive research. Despite the association with some tumors, a causal relationship has not been established. Some of the results on SAA1 remain controversial. In my opinion, the merit of the authors is that they first showed the downregulated expression of SAA1 in HCC, a decrease SAA1 expression with the increased tumor grade and disease stage. Ultimately the authors confirmed that the decreased SAA1 expression was involved in the progression of HCC. Moreover, the study identified 2 signature genes interacted with SAA1 (these data enhance the prognostic value of SAA1 in HCC). The fact that the SAA1 expression is associated with the anti-tumor immunity pathways, has an important translational value. Firstly, the lower SAA1 could be a potential therapeutic target. Furthermore, the downregulated expression of SAA1 can be used as a potential prognostic biomarker for HCC. The study was performed methodologically correct. The manuscript is well understood and easy to read. The authors provided well-constructed and well-annotated table and figures. The authors reasonably cite the latest, relevant, and comprehensive references without self-citation. In summary, the manuscript was prepared in a professional manner and certainly can be recommended for publication.